-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $323

Benzinga·11/02/2026 12:43:03
Canaccord Genuity analyst Whitney Ijem maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $429 to $323.